TREM2 on microglia normally binds complement C1q to prevent complement-mediated synaptic pruning of cholinergic terminals. In AD, TREM2 variants reduce this protective binding, leading to C1q-mediated attack on basal forebrain cholinergic synapses. A therapeutic approach using TREM2 agonism or C1q-blocking fragments would preserve cholinergic innervation.
**Background and Rationale** TREM2 variants represent major genetic risk factors for Alzheimer's disease, with loss-of-function mutations increasing dementia risk threefold. While TREM2 is exclusively expressed on microglia, emerging evidence suggests its primary pathogenic role occurs through disrupted astrocyte-microglia communication rather than intrinsic microglial dysfunction. Healthy brain homeostasis depends on coordinated responses between these glial populations, where TREM2+ microglia
Verdict Summary
4/10
dimensions won
TREM2-C1Q Competitive Binding to Prevent
6/10
dimensions won
TREM2-Dependent Astrocyte-Microglia Cros
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.75
0.88
Evidence
0.60
0.00
Novelty
0.70
0.00
Feasibility
0.45
0.00
Impact
0.65
0.00
Druggability
0.40
0.65
Safety
0.35
0.58
Competition
0.30
0.70
Data
0.55
0.85
Reproducible
0.60
0.75
Score Breakdown
Dimension
TREM2-C1Q Competitive Binding
TREM2-Dependent Astrocyte-Micr
Mechanistic
0.750
0.880
Evidence
0.600
0.000
Novelty
0.700
0.000
Feasibility
0.450
0.000
Impact
0.650
0.000
Druggability
0.400
0.650
Safety
0.350
0.580
Competition
0.300
0.700
Data
0.550
0.850
Reproducible
0.600
0.750
Evidence
TREM2-C1Q Competitive Binding to Prevent Complement-Mediated
No evidence citations yet
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
No evidence citations yet
Debate Excerpts
TREM2-C1Q Competitive Binding to Prevent Complemen
4 rounds · quality: 0.95
Theorist
## Novel Therapeutic Hypotheses: Causal Mechanisms in Cholinergic Dysfunction & AD Pathology
---
### Hypothesis 1: α7-nAChR/APP Physical Complex as a Pathological Feedback Driver
**Title:** Disru...
Skeptic
# Critical Evaluation of Novel Therapeutic Hypotheses in Cholinergic Dysfunction & Alzheimer's Disease
## Overview Assessment
The proposed framework presents an elegant **bidirectional amplificati...
Domain Expert
As of **April 16, 2026**, the practical answer is: **plaques and tangles are unlikely to be just a consequence of cholinergic dysfunction**. Human data support a model where **cholinergic failure is m...
Synthesizer
```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H5",
"title": "NLRP3 Inflammasome Priming of Basal Forebrain Cholinergic Neurons as the Earliest Vulnerability...
TREM2-Dependent Astrocyte-Microglia Cross-talk in
4 rounds · quality: 0.95
Theorist
Based on my research, I'll now generate novel therapeutic hypotheses focused on aging-related gene expression changes that predict neurodegenerative vulnerability. Here are 6 evidence-based therapeuti...
Skeptic
## Critical Evaluation of Therapeutic Hypotheses
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and counter-evidence:
### 1. **AP1S1-Mediated Vesicular Transport Restora...
Domain Expert
# Practical Feasibility Assessment of Therapeutic Hypotheses
Based on my analysis of druggability, existing compounds, competitive landscape, and development considerations, here's my comprehensive a...
Synthesizer
Based on my synthesis of the Theorist's hypotheses, Skeptic's critiques, and Expert's feasibility assessment, here's the final JSON output:
```json
{
"ranked_hypotheses": [
{
"rank": 1,
...